The EnClear Team

Mr. DePasqua is an operating executive and entrepreneur with 20 years of success guiding healthcare innovation in oncology, neurosurgery and orthopedics from concept through commercialization and wide market adoption.

 

Most recently head of BD & Strategy at Medtronic Advanced Energy. Mr. DePasqua started his career in marketing and sales for early stage med-tech companies such as Harvest Technologies (acquired by TERUMO) and Salient Surgical (acquired by Medtronic) before moving on to portfolio management, strategy and BD.

Mr. Hicks has nearly 25 years of experience in corporate development and business strategy execution within the biotechnology, pharmaceutical and venture capital segments. 

 

He has held senior leadership roles at several early-stage biotech startups including, Aker BioMarine (Senior Vice President of Business Development and Strategy), Travecta Therapeutics, Inc. (Chief Business Officer), and iBio, Inc (Senior Vice President of Business Development and Strategy). He began his career at Bristol-Myers Squibb and Clearview Projects, Inc. 

Mr. Kalish has 15+ years of experience leading R&D and Operations, launching a wide range of capital, disposable and implantable healthcare technology of industry leading companies. Starting his career at Johnson & Johnson before moving on to hold leadership positions at Boston Scientific and Medtronic.

 

Mr. Kalish currently serves as an advisor on the UMASS Biomedical Engineering board and is an adjunct professor at SNHU. He also serves as the acting COO at Apercu Diagnostics. An academic stage med-tech start up.

Chris Thomajan also serves as managing partner at TechCXO Boston, a professional services firm that provides experienced, C-suite professionals to deliver outsourced, strategic consulting services for technology companies.

 

Chris has deep experience working in the biotechnology sector and has been the founding CFO for outstanding companies such as Relay Therapeutics (RLAY), Keros Therapeutics (KROS), Catabasis Pharmaceuticals (CATB), Ribometrix, and Cyteir Therapeutics.

​

​

For the past 30 years, Dr. Glicksman has been dedicated to developing better therapeutics for the nervous system and other therapeutic areas. Her efforts have resulted in 8 drugs entering the clinic, 2 marketed drugs resulting in over $2B in sales for Cephalon (now Teva Pharmaceuticals) and Cubist (now Merck).

 

As a scientific leader Dr. Glicksman has been a key advisor for multiple foundations including the Michael J. Fox Foundation, Alzheimer's Association, and the National Multiple Sclerosis Society.

5+ years working closely with physician experts to develop the next generation of capital and implantable healthcare devices, most recently at Medtronic.

​

Mr. Patel holds a Masters of Engineering, Bioengineering and Biomedical Engineering from Cornel University. He currently serves as an engineering advisor to Apercu Diagnostics. An academic stage med-tech start up.